AbbVie’s ABBV stock has been trading above its 50-day and 200-day simple moving averages (SMAs) since early July. The 50-day ...

AbbVie ABBV stock has risen 8.0% in six months, adding more than $24 billion to its market value. AbbVie has successfully navigated the loss of exclusivity (“LOE”) of its blockbuster drug, Humira, by ...

Healthcare giants AbbVie and Abbott Laboratories are both Dividend Kings. In 2013, AbbVie (NYSE: ABBV) became a publicly ...

AbbVie has received European Commission approval of its anti-inflammation drug Skyrizi for the treatment of adult patients with moderately to severely active ulcerative colitis, the pharmaceutical ...

AbbVie’s Skyrizi took home the top spot for most pharma brand ad impressions in April, according to data released by iSpot.tv on Wednesday afternoon. The psoriasis treatment garnered an impressions ...

The healthcare industry is a behemoth, with annual expenditures totaling $4.9 trillion in the United States alone. It's a ...

For Capstan, AbbVie will pay up to $2.1 billion in cash, subject to certain customary adjustments. Capstan is backed by investors including Pfizer Ventures, Novartis Venture Fund, Eli Lilly and ...

This outperformance is indicative of investor confidence in the pharmaceutical giant's ambitious transformation strategy as it navigates the post-Humira period.

AbbVie’s $2.1 billion acquisition of Capstan Therapeutics aims to advance in vivo CAR-T therapies, transforming autoimmune disease treatment by resetting the immune system.

Realty Income(NYSE: O) is listed third among the dividend stocks to double up on now, but it's only because I've listed the stocks alphabetically. There's a lot to like about this real estate ...